John J Monahan
CIK 1257825 · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANIX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
627 DAVIS DRIVE, SUITE 300
MORRISVILLE, NC 27560
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TOVX | Director | — | $0.19 | — | $0 | 4 | 2026-01-06 |
| Scorpius Holdings, Inc. (NHWK) Delisted | Director | — | $0.41 | — | $0 | 1 | 2022-12-09 |
| Scorpius Holdings, Inc. (HTBX) Delisted | Director | 74 | $2.38 | $176 | $0 | 10 | 2022-01-03 |
| Theriva Biologics, Inc. (SYN) Delisted | Director | — | $1.02 | — | $0 | 2 | 2021-12-27 |
| ANIX | Director | 50,900 | $3.04 | $155.0K | $3.8K | 5 | 2020-08-17 |
| Anixa Biosciences Inc (ITUS) Delisted | Director | 50,000 | — | — | $0 | 4 | 2017-09-26 |
Recent Filings · Page 2 of 3
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-08-17 | ANIX | Grant (A) | — | $0 | EDGAR |
| 2020-01-02 | Scorpius Holdings, Inc. (HTBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-24 | ANIX | Grant (A) | — | $0 | EDGAR |
| 2019-09-20 | ANIX | Mixed | — | $0 | EDGAR |
| 2019-04-29 | ANIX | Buy (P) | +900 | $3.8K | EDGAR |
| 2019-01-03 | Scorpius Holdings, Inc. (HTBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-09 | ANIX | Grant (A) | — | $0 | EDGAR |
| 2018-01-10 | Scorpius Holdings, Inc. (HTBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-26 | Anixa Biosciences Inc (ITUS) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
| 2017-09-11 | Anixa Biosciences Inc (ITUS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.